2024
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-VÎČ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-VÎČ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2022
Safety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
2007
Mycosis Fungoides: Pathophysiology and Emerging Therapies
Duvic M, Foss FM. Mycosis Fungoides: Pathophysiology and Emerging Therapies. Seminars In Oncology 2007, 34: s21-s28. PMID: 18086343, DOI: 10.1053/j.seminoncol.2007.11.006.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesRefractory cutaneous T-cell lymphomaPrimary cutaneous T-cell lymphomaNeoplastic T lymphocytesSafe treatment strategyNon-Hodgkin lymphomaT-cell lymphomaLeukemic variant SĂ©zary syndromeHistone deacetylase inhibitorsOrgan complicationsSystemic regimensCutaneous manifestationsEmerging TherapiesSĂ©zary syndromeSkin infiltrationSystemic therapyBiologic agentsCTCL subtypesTreatment strategiesCurrent treatmentT lymphocytesDeacetylase inhibitorsPurine nucleoside phosphorylase inhibitorTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply